Viatris Inc
NASDAQ:VTRS

Watchlist Manager
Viatris Inc Logo
Viatris Inc
NASDAQ:VTRS
Watchlist
Price: 11.94 USD 2.05% Market Closed
Market Cap: 13.8B USD

Net Margin
Viatris Inc

-26.1%
Current
-3%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-26.1%
=
Net Income
-3.7B
/
Revenue
14.1B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Viatris Inc
NASDAQ:VTRS
13.8B USD
-26%
US
Eli Lilly and Co
NYSE:LLY
999.6B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
501.2B USD
27%
CH
Roche Holding AG
SIX:ROG
254.4B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.1B GBP
16%
CH
Novartis AG
SIX:NOVN
206.7B CHF
26%
US
Merck & Co Inc
NYSE:MRK
250.5B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.4B USD
16%
No Stocks Found

Viatris Inc
Glance View

In the bustling realm of pharmaceutical giants, Viatris Inc. has carved out a distinctive path since its inception in November 2020, born from the merger of Mylan N.V. and Pfizer’s Upjohn division. This union forged a new entity poised to leverage a vast portfolio of iconic brands and generic drugs. At its core, Viatris operates on a diversified business model, producing and distributing therapeutic solutions that range from well-known branded medications to complex generics and over-the-counter (OTC) products. With operations spanning across the globe, the company ensures the delivery of critical healthcare solutions to millions, focusing on accessibility and affordability. This global approach not only enhances its revenue streams but also strengthens its market resilience against regional disruptions. Strategically, Viatris has placed a hefty emphasis on integrating and optimizing supply chains, thereby maximizing operational efficiencies and profit margins. By successfully blending the robust generic drug capabilities of Mylan with the established brand strength of Pfizer’s Upjohn, Viatris is well-positioned to capture and sustain market share across diverse therapeutic categories. Additionally, Viatris invests heavily in research and development to expand its pipeline of complex generics and biosimilars, potentially paving the way for future growth and innovation. This strategic alignment allows the company to cater to a broad spectrum of patient needs and healthcare systems worldwide, making it a formidable player in the pharmaceutical industry.

VTRS Intrinsic Value
31.7 USD
Undervaluation 62%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-26.1%
=
Net Income
-3.7B
/
Revenue
14.1B
What is the Net Margin of Viatris Inc?

Based on Viatris Inc's most recent financial statements, the company has Net Margin of -26.1%.

Back to Top